Finance

Lists
Q3 2026 earnings • released • EPS beat +၆၀.၃၂% • Revenue beat +၂၇.၆၈%
See results
RNA:NASDAQ
Atrium Therapeutics Inc
၆.၅၂ US$
+၁.၄၈%
(+၀.၀၉၅) 1D
နို ၁၇, GMT-၅ ၁၅:၄၆:၃၄  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNA...
Open
၆.၄၆ US$
High
၆.၉၄ US$
Low
၆.၄၄ US$
Mkt. cap
၁၄.၀၈ ကုဋေ
Avg. vol.
၂.၃၇ သိန်း
Volume
၂.၆၈ သိန်း
52-wk high
၇၃.၀၆ US$
52-wk low
၆.၃၆ US$
EPS
-၄.၁၁ US$
Shares outstanding
၃.၆၁ ကုဋေ
No. of employees
၄၇
Open
၆.၄၆ US$
High
၆.၉၄ US$
Low
၆.၄၄ US$
Mkt. cap
၁၄.၀၈ ကုဋေ
Avg. vol.
၂.၃၇ သိန်း
Volume
၂.၆၈ သိန်း
52-wk high
၇၃.၀၆ US$
52-wk low
၆.၃၆ US$
EPS
-၄.၁၁ US$
Shares outstanding
၃.၆၁ ကုဋေ
No. of employees
၄၇
News stories
From web sources and news partners
Fox Business
Fox Business
·
ပြီးခဲ့သည့် ၅၉ မိနစ်
S&P 500 decline driven by semiconductor confidence issues, says Scott Chronert
MarketWatch
MarketWatch
·
ပြီးခဲ့သည့် ၃၄ မိနစ်
The S&P 500 is testing a key technical floor. Is it time to buy, or brace for a bear market?
MarketWatch
MarketWatch
·
ပြီးခဲ့သည့် ၃၁ မိနစ်
Only two ‘Magnificent Seven’ stocks have managed to beat the S&P 500 since the start of 2025
Traders Union
Traders Union
·
ပြီးခဲ့သည့် ၁ နာရီ
Bitcoin-to-S&P 500 ratio holds trendline support, James Van Straten notes
About Atrium Therapeutics Inc
CEO-
Employees၄၇
Founded၂၀၂၅
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 4 analysts giving stock ratings to RNA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for RNA in the last 3 months.
Highest
Current ၆.၅၂ US$
၂၅.၀၀ US$ (+၂၈၃.၁၄%)
Average
၂၁.၂၅ US$ (+၂၂၅.၆၇%)
Lowest
၁၅.၀၀ US$ (+၁၂၉.၈၉%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yanan Zhu
Wells Fargo
Buy
Reiterated
၂၅.၀၀ US$
+၂၈၃.၁%
11/16/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
၂၀.၀၀ US$
+၂၀၆.၅%
11/13/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
၁၅.၀၀ US$
+၁၂၉.၉%
11/13/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
၂၅.၀၀ US$
+၂၈၃.၁%
10/14/2026
David Siffringer
Cantor Fitzgerald
Buy
Initiated
၂၅.၀၀ US$
+၂၈၃.၁%
06/18/2026
Joseph Schwartz
Leerink Partners
Buy
Initiated
၂၅.၀၀ US$
+၂၈၃.၁%
05/15/2026
Last report
၂၀၂၆ နို ၁၂
Fiscal period
Q3 2026
-၀.၂၅ US$ / -၀.၆၃ US$
+၆၀.၃၂%beat
Revenue / Est. (USD)
၁.၅၃ ကုဋေ / ၁.၂၀ ကုဋေ
+၂၇.၆၈%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၈.၅၉ သိန်း
၁.၉၆ ကုဋေ
၃.၀၀ သန်း
၁.၅၃ ကုဋေ
Cost of goods sold
၁.၄၃ ကုဋေ
၁.၆၇ ကုဋေ
၁.၅၃ ကုဋေ
-
Cost of revenue
၁.၄၃ ကုဋေ
၁.၆၇ ကုဋေ
၁.၅၃ ကုဋေ
-
Research and development expenses
-
-
-
၁.၃၈ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၁.၅၇ ကုဋေ
၂.၀၃ ကုဋေ
၁.၀၃ ကုဋေ
၈.၁၅ သန်း
Operating expense
၁.၅၇ ကုဋေ
၂.၀၃ ကုဋေ
၁.၀၃ ကုဋေ
၂.၂၀ ကုဋေ
Total operating expenses
၃.၀၀ ကုဋေ
၃.၆၉ ကုဋေ
၂.၅၆ ကုဋေ
၂.၂၀ ကုဋေ
Operating income
-၂.၉၁ ကုဋေ
-၁.၇၃ ကုဋေ
-၂.၂၆ ကုဋေ
-၆.၆၃ သန်း
Other non operating income
-
၆.၄၇ သိန်း
၃.၂၈ သိန်း
၁.၇၇ သိန်း
EBT including unusual items
-၂.၉၁ ကုဋေ
-၁.၆၆ ကုဋေ
-၂.၀၂ ကုဋေ
-၄.၂၇ သန်း
EBT excluding unusual items
-၂.၉၁ ကုဋေ
-၁.၆၆ ကုဋေ
-၂.၀၂ ကုဋေ
-၄.၂၇ သန်း
Income tax expense
၃.၄၀ သောင်း
-
-
-
Effective tax rate
-၀.၁၂%
-
-
-
Other operating expenses
-
-
-
-
Net income
-၂.၉၁ ကုဋေ
-၁.၆၆ ကုဋေ
-၂.၀၂ ကုဋေ
-၄.၂၇ သန်း
Net profit margin
-၃,၃၉၁.၈၅%
-၈၄.၇၁%
-၆၇၁.၉၇%
-၂၇.၈၄%
Earnings per share
-
-
-၁.၁၈
-၀.၂၅
Interest and investment income
-
-
၂.၁၀ သန်း
၂.၁၉ သန်း
Interest expense
-
-
-
-
Net interest expenses
-
-
၂.၁၀ သန်း
၂.၁၉ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၂.၉၀ ကုဋေ
-၁.၇၁ ကုဋေ
-၂.၂၃ ကုဋေ
-၆.၂၈ သန်း
Gain or loss from assets sale
၁.၄၀ သိန်း
-
-
-၆.၁၀ သောင်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ